---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-164789"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2025-07-25T23:59:59+00:00"
generated_at: "2026-05-18T00:57:56.234450+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio raises $80M equity; Q2 revenue $26.4M (+60% QoQ), ANKTIVA units up 246%

## Summary
- Registered direct offering of 29.6M shares and warrants at $2.70/unit, gross proceeds ~$80M.
- Q2 2025 revenue $26.4M, up 60% from Q1 2025; year-to-date sales ~$43M.
- Cash and equivalents $153.7M as of June 30, 2025.
- FDA refused to file supplemental BLA for papillary NMIBC; company re-evaluating approach with new data.
- UK MHRA approved ANKTIVA marketing authorization; NSCLC RCT initiated in US.

## SEC filing metadata
- accession: 0001193125-25-164789
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2025-07-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000119312525164789/0001193125-25-164789-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000119312525164789/d20571d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-164789
- JSON: https://secwatch.observer/filing/0001193125-25-164789.json
- Plain text: https://secwatch.observer/filing/0001193125-25-164789.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.